PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes

(2011) Fatemeh Namvaran et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Novel thiazolidinedione derivatives with anti-obesity effects: Dual action as PTP1B inhibitors and PPAR-γ activators

(2010) Bharat Raj Bhattarai et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients

(2010) Qiong Huang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Common polymorphisms of the peroxisome proliferator-activated receptor–γ (Pro12Ala) and peroxisome proliferator-activated receptor–γ coactivator–1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

(2010) Ming-Chia Hsieh et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

A Genome-Wide Association Study Identifies Susceptibility Variants for Type 2 Diabetes in Han Chinese

(2010) Fuu-Jen Tsai et al.   PLoS Genetics

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

(2009) Elizabeth B Daily et al.   PHARMACOGENOMICS

Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats

(2005) Yong Wu et al.   BRITISH JOURNAL OF PHARMACOLOGY